Results 121 to 130 of about 1,044,683 (223)

Pharmacokinetic evaluation of paclitaxel, albumin-binding paclitaxel, and liposomal-encapsulated albumin-binding paclitaxel upon gastric subserosal administration [PDF]

Introduction: Systemic chemotherapy is typically administered following radical gastrectomy for advanced stage. To attenuate systemic side effects, we evaluated the effectiveness of regional chemotherapy using paclitaxel, albumin-paclitaxel, and liposome-
In Ho Song, Sun Mi Park, Hyun Soo Park, Hyung-Ho Kim, Yoontaek Lee, Byung Seok Moon, Bom Sahn Kim   +6 more
core   +1 more source

Human biomarker navigator

iMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Efficacy and Safety of Co‐Ablation Combined With Aintilimab for Metastatic Melanoma to the Liver (CryoCheck‐001): A Phase II Trial

MedComm, Volume 7, Issue 10, October 2026.
Liver metastasis is a key driver of immune tolerance in patients with melanoma receiving immune checkpoint inhibitor therapy. This single‐arm phase II trial prospectively investigated the efficacy and safety of co‐ablation combined with sintilimab for liver metastatic melanoma.
Lujun Shen, Letao Lin, Shuanggang Chen, Chen Li, Ruizhi Tang, Lin Xie, Yujia Wang, Yunpeng Li, Hongliang Zou, Dandan Li, Xiaoshi Zhang, Weijun Fan   +11 more
wiley   +1 more source

Albumin-bound Paclitaxel Regimen [PDF]

, 2020
openaire   +1 more source

Iron and Other Metal Ions in Human Health and Disease

MedComm, Volume 7, Issue 10, October 2026.
Iron, copper, zinc, and calcium orchestrate cellular function through distinct yet cooperative mechanisms: redox‐active iron and copper cycle between oxidation states to act as Fenton catalysts and electron carriers in oxidative phosphorylation (OXPHOS); redox‐inert zinc serves as a structural component of zinc‐finger proteins and a catalytic cofactor ...
Xiaofeng Dai, Jitian Li
wiley   +1 more source

181227S1fig – Supplemental material for Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System

, 2019
Supplemental material, 181227S1fig for Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System by Misa Naganuma, Kohei Tahara, Shiori Hasegawa ...
Haruna Hatahira (3207483), Kouseki Hirade (4264786), Kohei Tahara (1516240), Takeshi Kato (2404825), Yumi Motooka (3207480), Mitsuhiro Nakamura (308371), Akiho Fukuda (3207465), Satoshi Nakao (2258755), Hirofumi Takeuchi (2873219), Sayaka Sasaoka (3207477), Misa Naganuma (3207471), Tomoaki Yoshimura (4589350), Shiori Hasegawa (2802643), Ririka Mukai (6447422)   +13 more
core   +1 more source

Erlotinib‐Induced Pneumatosis Intestinalis: A Case Report and Review of Literature

Respirology Case Reports, Volume 14, Issue 10, October 2026.
We report a rare case of erlotinib‐induced pneumatosis intestinalis that worsened during continued treatment and rapidly improved after erlotinib discontinuation. This case highlights the importance of recognizing pneumatosis intestinalis as a potential adverse event of EGFR‐TKIs. ABSTRACT Pneumatosis intestinalis (PI) is a rare condition characterized
Shunsuke Saito, Koki Nakashima, Kaede Yokoyama, Ai Takeuchi, Makiko Yamaguchi, Yukihiro Umeda, Yuko Waseda   +6 more
wiley   +1 more source

190124S1Table – Supplemental material for Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System

, 2019
Supplemental material, 190124S1Table for Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System by Misa Naganuma, Kohei Tahara, Shiori Hasegawa,
Haruna Hatahira (3207483), Kouseki Hirade (4264786), Kohei Tahara (1516240), Takeshi Kato (2404825), Yumi Motooka (3207480), Mitsuhiro Nakamura (308371), Akiho Fukuda (3207465), Satoshi Nakao (2258755), Hirofumi Takeuchi (2873219), Sayaka Sasaoka (3207477), Misa Naganuma (3207471), Tomoaki Yoshimura (4589350), Shiori Hasegawa (2802643), Ririka Mukai (6447422)   +13 more
core   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, Volume 7, Issue 5, October 2026.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Interferometric Scattering Microscopy of Albumin-bound Paclitaxel Nanoparticles

Microscopy and Microanalysis, 2022
Matthew Licausi, Aengus Vervier, Shakiba Nikfarjam, Taylor J Woehl   +3 more
openaire   +1 more source